FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317993340> ?p ?o ?g. }

• W2317993340 abstract "IL-2 therapy can result in durable responses in a proportion of cancer patients, but the treatment is associated with significant toxicity. To improve the liabilities associated with IL-2 therapy, we recently developed a novel monomeric tumor-targeted immunocytokine (CEA-IL2v), which completely lacks binding to CD25 (IL-2Rα) but retains binding to IL-2Rβγ. When tested in classical 2D tumor/lymphocyte co-culture systems, CEA-IL2v induces concentration-dependent proliferation and activation of NK, CD4 and CD8 T cells, but differently from IL-2, does not lead to preferential activation of Tregs and induces lower levels Fas-induced apoptosis. To further explore the properties of CEA-IL2v, including the assessment of antibody targeting and stimulation of immune-cell activation and infiltration, we developed a novel 3D heterotypic microtissues model consisting of tumor cells, fibroblasts and lymphocytes. To address the penetration and targeting, heterotypic 3D microtissues consisting of CEA-expressing human tumor cells and fibroblasts were incubated with tumor-targeted IL-2v (CEA-IL2v), stroma-targeted IL-2v (FAP-IL2v), and the corresponding untargeted control (DP47-IL2v). CEA-IL2v successfully penetrated into microtissues and specifically bound to CEA-positive tumor cells, FAP-IL2v was specifically retained by FAP-expressing fibroblasts whereas the DP47-IL2v was not detected in any of the components. The activity of the immunocytokines was further evaluated by addition of human lymphocytes to 3D microtissues. CEA-IL2v and DP47-IL2v activated different lymphocyte subsets, stimulated their infiltration and selectively promoted the elimination of tumor cells as shown by (a) reduction of microtissue size, (b) increase of LDH release, (c) elimination of CEA-positive tumor cells, (d) increase of lymphocytes infiltrating into the microtissues and (e) increase of cytokine and chemokine levels secreted in the supernatants, including MIP-1β, IL-6 and IFN-γ. Taken together, the heterotypic tumor/fibroblast/lymphocyte 3D microtissue model presented here offers the possibility to monitor antibody penetration and targeting to tumor and stroma components, to study the interaction of tumor cells with immune cells in a system that more closely resembles the in vivo tumor microenvironment and thus provides an in vitro platform for optimal immunotherapy development. The study also points out that the tumor-targeted CEA-IL2v immunocytokine is an elegant tool for expansion and activation of immune effector cells, which may successfully be applied for cancer immunotherapy. Citation Format: Inja Waldhauer, Laura Morra, Steffi Lehmann, Irina Agarkova, Philine Zumstein, Jens M. Kelm, Pablo Umana, Christian Klein, Marina Bacac. Development of 3D microtissue models to study the activity of novel tumor-targeted immunotherapeutics. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-264. doi:10.1158/1538-7445.AM2013-LB-264" @default.
• W2317993340 created "2016-06-24" @default.
• W2317993340 creator A5002292400 @default.
• W2317993340 creator A5025443530 @default.
• W2317993340 creator A5040318787 @default.
• W2317993340 creator A5047334223 @default.
• W2317993340 creator A5057235269 @default.
• W2317993340 creator A5061889800 @default.
• W2317993340 creator A5067162282 @default.
• W2317993340 creator A5075578054 @default.
• W2317993340 creator A5083722331 @default.
• W2317993340 date "2013-04-15" @default.
• W2317993340 modified "2023-09-27" @default.
• W2317993340 title "Abstract LB-264: Development of 3D microtissue models to study the activity of novel tumor-targeted immunotherapeutics." @default.
• W2317993340 doi "https://doi.org/10.1158/1538-7445.am2013-lb-264" @default.
• W2317993340 hasPublicationYear "2013" @default.
• W2317993340 type Work @default.
• W2317993340 sameAs 2317993340 @default.
• W2317993340 citedByCount "0" @default.
• W2317993340 crossrefType "proceedings-article" @default.
• W2317993340 hasAuthorship W2317993340A5002292400 @default.
• W2317993340 hasAuthorship W2317993340A5025443530 @default.
• W2317993340 hasAuthorship W2317993340A5040318787 @default.
• W2317993340 hasAuthorship W2317993340A5047334223 @default.
• W2317993340 hasAuthorship W2317993340A5057235269 @default.
• W2317993340 hasAuthorship W2317993340A5061889800 @default.
• W2317993340 hasAuthorship W2317993340A5067162282 @default.
• W2317993340 hasAuthorship W2317993340A5075578054 @default.
• W2317993340 hasAuthorship W2317993340A5083722331 @default.
• W2317993340 hasConcept C153400128 @default.
• W2317993340 hasConcept C159985019 @default.
• W2317993340 hasConcept C167672396 @default.
• W2317993340 hasConcept C185592680 @default.
• W2317993340 hasConcept C192562407 @default.
• W2317993340 hasConcept C203014093 @default.
• W2317993340 hasConcept C2776107976 @default.
• W2317993340 hasConcept C3020616263 @default.
• W2317993340 hasConcept C502942594 @default.
• W2317993340 hasConcept C71924100 @default.
• W2317993340 hasConcept C8891405 @default.
• W2317993340 hasConceptScore W2317993340C153400128 @default.
• W2317993340 hasConceptScore W2317993340C159985019 @default.
• W2317993340 hasConceptScore W2317993340C167672396 @default.
• W2317993340 hasConceptScore W2317993340C185592680 @default.
• W2317993340 hasConceptScore W2317993340C192562407 @default.
• W2317993340 hasConceptScore W2317993340C203014093 @default.
• W2317993340 hasConceptScore W2317993340C2776107976 @default.
• W2317993340 hasConceptScore W2317993340C3020616263 @default.
• W2317993340 hasConceptScore W2317993340C502942594 @default.
• W2317993340 hasConceptScore W2317993340C71924100 @default.
• W2317993340 hasConceptScore W2317993340C8891405 @default.
• W2317993340 hasLocation W23179933401 @default.
• W2317993340 hasOpenAccess W2317993340 @default.
• W2317993340 hasPrimaryLocation W23179933401 @default.
• W2317993340 hasRelatedWork W1568263254 @default.
• W2317993340 hasRelatedWork W1573980104 @default.
• W2317993340 hasRelatedWork W1607188844 @default.
• W2317993340 hasRelatedWork W1829560991 @default.
• W2317993340 hasRelatedWork W1967789051 @default.
• W2317993340 hasRelatedWork W1993543117 @default.
• W2317993340 hasRelatedWork W1994821067 @default.
• W2317993340 hasRelatedWork W1997080388 @default.
• W2317993340 hasRelatedWork W2005842767 @default.
• W2317993340 hasRelatedWork W2080723132 @default.
• W2317993340 hasRelatedWork W2109616567 @default.
• W2317993340 hasRelatedWork W2147828284 @default.
• W2317993340 hasRelatedWork W2322050194 @default.
• W2317993340 hasRelatedWork W2325832391 @default.
• W2317993340 hasRelatedWork W2550234446 @default.
• W2317993340 hasRelatedWork W2587548784 @default.
• W2317993340 hasRelatedWork W2740649611 @default.
• W2317993340 hasRelatedWork W2793552794 @default.
• W2317993340 hasRelatedWork W2956098846 @default.
• W2317993340 hasRelatedWork W3013079331 @default.
• W2317993340 isParatext "false" @default.
• W2317993340 isRetracted "false" @default.
• W2317993340 magId "2317993340" @default.
• W2317993340 workType "article" @default.